DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions

Information source: Central Hospital, Nancy, France
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bariatric Surgery; Laparoscopic Bariatric Surgery; Robotic Bariatric Surgery; Gastric Bypass; Morbid Obesity

Intervention: rocuronium (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Central Hospital, Nancy, France

Official(s) and/or principal investigator(s):
Thomas Fuchs-Buder, MD, Principal Investigator, Affiliation: CHU Nancy, Department of Anaesthesia & Critical Care

Overall contact:
Thomas Fuchs-Buder, MD, Phone: #33.383.153942, Email: t.fuchs-buder@chu-nancy.fr


The purpose of this study is to determine whether deep neuromuscular blockade compared to moderate neuromuscular blockade may improve the surgical conditions in patients undergoing laparoscopic bariatric surgery.

Clinical Details

Official title: Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care

Primary outcome: Improvement of surgical conditions

Secondary outcome: Pneumoperitoneum generated pressure


Minimum age: 18 Years. Maximum age: 64 Years. Gender(s): Both.


Inclusion Criteria:

- patient between 18 and 64 years

- indication for bariatric surgery accordingly to HAS

- patient undergoing laparoscopic or robotic gastric bypass surgery

- written informed consent

- affiliation to social security

Non-inclusion Criteria:

- known hypersensibility to any of the drugs used during this study

- absence of written informed consent

Locations and Contacts

Thomas Fuchs-Buder, MD, Phone: #33.383.153942, Email: t.fuchs-buder@chu-nancy.fr

CHU Nancy/Brabois, Vandoeuvre-Les-Nancy F-54511, France; Recruiting
Thomas Fuchs-Buder, MD, Phone: #33.383.153942, Email: t.fuchs-buder@chu-nancy.fr
Thomas Fuchs-Buder, MD, Principal Investigator
Claude Meistelman, MD, Sub-Investigator
Laurent Brunaud, MD, PhD, Sub-Investigator
Denis Schmartz, MD, Sub-Investigator
Valérie Jacques, MD, Sub-Investigator
Thibaut Fouquet, MD, Sub-Investigator
Thomas Serradoni, MD, Sub-Investigator
Claire Nominé, MD, Sub-Investigator
Additional Information

Starting date: July 2014
Last updated: July 29, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017